Press Releases Stay on top of the latest news from Poseida Therapeutics. Learn about our leading-edge cell and gene therapy programs, from new discoveries to clinical trials, and get the most recent investor news. IR Sub Menu Investors & Media Corporate Profile Press Releases Events & Presentations Publications Year None202320222021202020192018201720162015 Poseida Therapeutics Announces Board Change 01/31/2023 Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition 12/11/2022 Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress 12/06/2022 Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 11/10/2022 Poseida Therapeutics to Present at Two Upcoming Investor Conferences 11/08/2022 Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress 11/03/2022 Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition 11/03/2022 Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting 10/05/2022 Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference 09/07/2022 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 112
Year None202320222021202020192018201720162015 Poseida Therapeutics Announces Board Change 01/31/2023 Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition 12/11/2022 Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress 12/06/2022 Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2022 11/10/2022 Poseida Therapeutics to Present at Two Upcoming Investor Conferences 11/08/2022 Poseida Therapeutics to Present at the ESMO Immuno-Oncology 2022 Annual Congress 11/03/2022 Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition 11/03/2022 Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting 10/05/2022 Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference 09/07/2022 Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last » Displaying 1 - 10 of 112
Poseida Therapeutics Presents Preclinical Data from P-FVIII-101 Gene Therapy for Hemophilia A at the 64th ASH Annual Meeting & Exposition 12/11/2022
Poseida Therapeutics to Present Early Data from Phase 1 Trials of P-MUC1C-ALLO1 and P-BCMA-ALLO1 at ESMO Immuno-Oncology 2022 Annual Congress 12/06/2022
Poseida Therapeutics Announces Oral Presentation Highlighting P-FVIII-101 Gene Therapy at the 64th ASH Annual Meeting & Exposition 11/03/2022
Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting 10/05/2022
Poseida Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference 09/07/2022
Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2022 08/11/2022